MarketMoodz
Takeda’s AI-Designed Zasocitinib Tops Sotyktu in Phase 3
Takeda reported topline Phase 3 LATITUDE Atlas results showing its AI-designed oral JAK inhibitor zasocitinib (TAK-279) achieved statistical superiority over Bristol Myers Squibb’s Sotyktu (deucravacitinib) for complete skin clearance (PASI 100) at week 16. The win — accompanied by superior PASI 90 and sPGA 0 results and no new safety signals — bolsters Takeda’s psoriasis franchise and highlights AI’s growing role in drug discovery.
Key Takeaways
- Zasocitinib demonstrated statistical superiority to deucravacitinib for the primary endpoint PASI 100 (complete skin clearance) at week 16.
- More than 35% of zasocitinib-treated patients achieved PASI 100 at week 16, about 2.5x the response rate of deucravacitinib and with separation as early as week 8.
- Key secondary endpoints—PASI 90 and sPGA 0 at week 16—also favored zasocitinib, and no new safety signals were reported.
- Takeda plans to present full LATITUDE data at medical congresses and aims to begin filing New Drug Applications with the FDA and other regulators this fiscal year.
- If approved, Takeda previously projected peak annual sales for zasocitinib of $3 billion to $6 billion, a potential market disruptor in oral psoriasis therapies.
People Involved
- Linda Stein GoldInvestigator, LATITUDE Atlas trial
Entities Involved
- Takeda Pharmaceutical (TAK)Developer of zasocitinib (TAK-279); sponsor of LATITUDE Atlas Phase 3
- Bristol Myers Squibb (BMY)Developer of Sotyktu (deucravacitinib), competitor oral psoriasis therapy
- Sotyktu (deucravacitinib)Competitor oral TYK2 inhibitor for moderate-to-severe plaque psoriasis
- U.S. Food and Drug Administration (FDA)Regulatory authority; target for planned NDA filings
MarketMoodz Analysis
For investors, a head-to-head Phase 3 win over Sotyktu immediately reshapes competitive expectations in the oral psoriasis market. Topline superiority on PASI 100, plus stacked wins on PASI 90 and sPGA 0, suggests stronger efficacy versus an approved oral standard; that can translate into faster uptake, higher pricing power, and a larger addressable share if safety and real-world tolerability hold up. Takeda’s plan to start NDA filings this fiscal year accelerates the timeline for potential revenue recognition and valuation re-rating, particularly given the company’s prior $3–6 billion peak-sales estimate for the asset.
The result also validates, at least anecdotally, the promise of AI-led drug discovery as a commercial differentiator. Zasocitinib was developed using artificial intelligence workflows, and a successful approval would strengthen investor appetite for biotechs and pharma investing heavily in AI to compress R&D timelines and lower early-stage costs. Historical context matters: head-to-head Phase 3 victories have repeatedly swung market share in specialty therapeutics—think JAKs and biologics shifts over the past decade—so analysts will re-run market-share, pricing, and peak-sales scenarios for Takeda, BMS, and peers such as AbbVie.
What to watch next: the full LATITUDE Atlas dataset (safety details, subgroup analyses, durability beyond week 16) at upcoming congress presentations, formal NDA submissions and regulatory feedback, and early commercial talk around label, positioning, and pricing. Key risks remain: topline claims require independent verification, the absence of new safety signals in topline data doesn’t replace complete safety adjudication, and payers will scrutinize cost-effectiveness against established biologics and oral options. Investors should focus on the timing of detailed data release, regulatory review milestones, and any analyst revisions to sales forecasts.
Source: Original Article